Notícias
Apenas manchetes de alto sinal - eventos macro, resultados, M&A, regulatório. Listicles e clickbait de analistas filtrados por padrão. Atualizado a cada hora.
109last 24h
3129last 7d
511● bullish (7d)
313● bearish (7d)
227publishers
Motley Fool160d agoneutral
CRISPR Therapeutics' Secret Weapon That Many Investors Are OverlookingSimply Wall St.160d agoneutral
CRISPR Therapeutics Conferences May Reframe Valuation Gap And Growth OutlookMotley Fool161d agobullish
CRISPR Therapeutics vs. Editas Medicine: Which Gene Editing Stock Is a Better Buy in 2026?Insider Monkey163d agoneutral
Is CRISPR Therapeutics (CRSP) One Of The Under-The-Radar Stocks With Massive Upside For 2026?Motley Fool167d agoneutral
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics?Simply Wall St.168d agoneutral
Assessing CRISPR Therapeutics (CRSP) Valuation After Narrower Q1 2026 Loss And Pipeline ProgressSimply Wall St.174d agoneutral
CRISPR Therapeutics Enters Second Phase As CASGEVY Uptake And Data BuildMarketBeat177d agoneutral
CRISPR Therapeutics Enters 'Second Phase' as CASGEVY Momentum Builds, Pipeline Data LoomsSimply Wall St.186d agobullish
Is It Time To Reconsider CRISPR Therapeutics (CRSP) After A 58% One Year Rally?Motley Fool192d agoneutral
What's the Next Big Thing After GLP-1 Drugs? CRISPR Therapeutics May Have the Answer.Simply Wall St.193d agoneutral
Why CRISPR Therapeutics (CRSP) Is Down 10.1% After Casgevy’s Strong Early Launch Metrics And Earnings Hopes